Abstract
Purpose: The aim of the study was to investigate the effect of deficiency of hMLH1 and hMSH2 expression on the prognosis of early gastric cancer (EGC) in Chinese populations. Methods: A total of 160 EGC patients who underwent curative gastrectomy with lymphadenectomy from January 2011 to July 2014 at Xinhua Hospital were evaluated. The expression rates of hMLH1 and hMSH2 were examined using tissues preserved in paraffin blocks by immunohistochemical staining. The clinicopathological characteristics and prognosis of EGC with deficient hMLH1 and hMSH2 were analyzed. Results: On immunohistochemical staining, the loss expression of hMLH1 and hMSH2 were observed in 89 (55.6%) and 45 (28.1%), respectively. The hMLH1 deficiency was associated with the middle third of tumor location (P = 0.041). According to Kaplan-Meier survival analysis and Log-Rank test, the loss expression of hMLH1 and hMSH2 were associated with worse survival than positive hMLH1 (HR = 0.247, 95% CI = 0.078-0.781, P = 0.017) and hMSH2 (HR = 0.174, 95% CI = 0.051-0.601, P = 0.006) in EGC. Conclusion: The main conclusions were as follows: The hMLH1 deficiency was preferred to the middle third of EGC. Lymph node metastasis (LNM) was a prognostic factor of EGC. And the prognosis of EGC patients with deficient mismatch repair (dMMR, mainly including deficient hMLH1 and hMSH2) was obviously worse than proficient mismatch repair (pMMR).
Introduction
Early gastric cancer (EGC), defined as a lesion confined to the mucosa or submucosa, typically carries an excellent prognosis, with five-year survival rates often exceeding 90%. However, a subset of patients still experiences recurrence or poor outcomes. Identifying which patients fall into this high-risk category remains a clinical challenge.
The Mismatch Repair (MMR) system is a critical DNA "spell-checker" that maintains genomic stability. While the prognostic value of MMR deficiency (dMMR) is well-established in colorectal cancer, its role in EGC has been controversial. This study investigates whether the expression levels of two key MMR proteins, hMLH1 and hMSH2, can serve as reliable prognostic indicators for EGC patients in Chinese populations.
Methods
The researchers conducted a retrospective study of 160 EGC patients who underwent curative gastrectomy at Xinhua Hospital (Shanghai) between 2011 and 2014. The mean follow-up duration was 3.65 years.
Immunohistochemical (IHC) staining was performed on paraffin-embedded tumor tissues to detect the presence of hMLH1 and hMSH2. "Deficiency" was defined as positive staining in less than 10% of tumor cells.
Statistical analysis employed Chi-square tests to correlate protein expression with clinicopathological features. Survival outcomes were analyzed using Kaplan-Meier curves and the Log-Rank test, while independent prognostic factors were identified via the Cox proportional hazards model.
Results
The study revealed a high prevalence of MMR deficiency even in early-stage cancer. Loss of hMLH1 expression was observed in 55.6% of samples, while hMSH2 deficiency was found in 28.1%. Notably, hMLH1 deficiency was significantly associated with tumors located in the middle third of the stomach ($P = 0.041$).
The most significant finding was the divergence in survival rates:
- hMLH1: The 5-year post-operative survival rate for patients with proficient hMLH1 was 98.6%, compared to only 85.5% for those with deficient hMLH1 ($P = 0.009$).
- Hazard Ratios: Loss of hMLH1 expression (HR = 0.247, $P = 0.017$) and hMSH2 expression (HR = 0.174, $P = 0.006$) were both strong predictors of poor outcomes.
Overall, the prognosis for patients with deficient mismatch repair (dMMR) was significantly worse than those with proficient mismatch repair (pMMR). Lymph node metastasis (LNM) was also confirmed as an independent prognostic factor.
Discussion and Conclusion
In contrast to some findings in advanced gastric cancer or colorectal cancer where dMMR may correlate with a better prognosis, dMMR appears to be a "poor prognostic factor" in EGC. This suggests that MMR status provides critical prognostic value independent of traditional factors like LNM.
Limitations of this study include its retrospective nature and the relatively small sample size from a single center. Future multi-center studies are needed to confirm these findings and to explore the molecular mechanisms by which MMR deficiency drives more aggressive behavior in early-stage gastric lesions. Additionally, the impact of dMMR status on chemotherapy sensitivity in EGC remains an important area for future clinical research.
In conclusion, deficiency of hMLH1 and hMSH2 is a significant marker for identifying high-risk EGC patients who may require more intensive follow-up or alternative treatment strategies.
Summary updated